Severe acute pancreatitis secondary to the use of immune checkpoint inhibitors
DOI:
https://doi.org/10.47892/rgp.2026.461.2062Keywords:
Immune Checkpoint Inhibitors, Acute Pancreatitis, Necrosis, Endosonographic, ColombiaAbstract
ICI-induced pancreatic injury is a rare subtype of immune-related adverse events. Although it is a relatively rare event and most patients who present it are asymptomatic, a subgroup of patients may present clinical and radiological manifestations typical of severe acute pancreatitis, with long-term sequelae of endo- and exocrine pancreatic function. Advanced age, the combination of ICIs, preexisting autoimmune diseases, and tumor type have been described as risk factors for developing this pathology. We report the case of a patient with metastatic renal cancer, a history of partial pancreatectomy, treated with checkpoint inhibitors, who developed severe acute pancreatitis with the formation of walled-off pancreatic necrosis after the third application. Other etiologies were ruled out; multidisciplinary management and endoscopic management with endosonographic drainage with apposition stent were provided, with a successful outcome and clinical recovery of the patient.
Downloads
References
Mederos MA, Reber HA, Girgis MD. Incorrect Positive Predictive Values Reported. JAMA. 2021;325(23):2405. doi: 10.1001/jama.2021.5789.
Saini J, Marino D, Badalov N, Vugelman M, Tenner S. DrugInduced Acute Pancreatitis: An Evidence-Based Classification (Revised). Clin Transl Gastroenterol. 2023;14(8):e00621. doi: 10.14309/ctg.0000000000000621.
Abu-Sbeih H, Tang T, Lu Y, Thirumurthi S, Altan M, Jazaeri AA, Dadu R, Coronel E, Wang Y. Clinical characteristics and outcomes of immune checkpoint inhibitor-induced pancreatic injury. J Immunother Cancer. 2019;7(1):31. doi: 10.1186/ s40425-019-0502-7.
Postow MA, Sidlow R, Hellmann MD. Immune-Related Adverse Events Associated with Immune Checkpoint Blockade. N Engl J Med. 2018;378(2):158-168. doi: 10.1056/NEJMra1703481.
Lin HF, Liao KF, Chang CM, Lin CL, Lai SW. Association of use of selective serotonin reuptake inhibitors with risk of acute pancreatitis: a case-control study in Taiwan. Eur J Clin Pharmacol. 2017;73(12):1615-1621. doi: 10.1007/s00228-017- 2328-x.
Ljung R, Rück C, Mattsson F, Bexelius TS, Lagergren J, Lindblad M. Selective serotonin reuptake inhibitors and the risk of acute pancreatitis: a Swedish population-based case-control study. J Clin Psychopharmacol. 2012;32(3):336-40. doi: 10.1097/ JCP.0b013e318253d71a.
Nørgaard M, Jacobsen J, Gasse C, Pedersen L, Mortensen PB, Sørensen HT. Selective serotonin reuptake inhibitors and risk of acute pancreatitis: a population-based case-control study. J Clin Psychopharmacol. 2007;27(3):259-62. doi: 10.1097/ JCP.0b013e318058a9c3.
Thompson JA, Schneider BJ, Brahmer J, Andrews S, Armand P, Bhatia S, et al. Management of Immunotherapy-Related Toxicities, Version 1.2019. J Natl Compr Canc Netw. 2019;17(3):255-289. doi: 10.6004/jnccn.2019.0013.
Kwok G, Yau TC, Chiu JW, Tse E, Kwong YL. Pembrolizumab (Keytruda). Hum Vaccin Immunother. 2016;12(11):2777-2789. doi: 10.1080/21645515.2016.1199310.
George J, Bajaj D, Sankaramangalam K, Yoo JW, Joshi NS, Gettinger S, et al. Incidence of pancreatitis with the use of immune checkpoint inhibitors (ICI) in advanced cancers: A systematic review and meta-analysis. Pancreatology. 2019;19(4):587-594. doi: 10.1016/j.pan.2019.04.015.
Nwankwo OC, Lara-Salazar FM, Lara-Salazar S, Abdulrahim AO, Chijioke I, Singh J, et al. Immune Checkpoint Inhibitors in Cancer Treatment and Incidence of Pancreatitis. Cureus. 2024;16(8):e68043. doi: 10.7759/cureus.68043.
Rogers BB, Cuddahy T, Zawislak C. Management of Acute Pancreatitis Associated With Checkpoint Inhibitors. J Adv Pract Oncol. 2020;11(1):49-62. doi: 10.6004/jadpro.2020.11.1.3.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Lázaro Arango Molano, Andrés Sánchez Gil, Fabian Puentes Manosalva, Karla Patricia Gutiérrez de la Peña, Herney Solarte Pineda, Santiago Salazar Ochoa

This work is licensed under a Creative Commons Attribution 4.0 International License.
Revista de Gastroenterología del Perú by Sociedad Peruana de Gastroenterología del Perú is licensed under a Licencia Creative Commons Atribución 4.0 Internacional..
Aquellos autores/as que tengan publicaciones con esta revista, aceptan los términos siguientes:
- Los autores/as conservarán sus derechos de autor y garantizarán a la revista el derecho de primera publicación de su obra, el cuál estará simultáneamente sujeto a la Licencia de reconocimiento de Creative Commons que permite a terceros compartir la obra siempre que se indique su autor y su primera publicación esta revista.
- Los autores/as podrán adoptar otros acuerdos de licencia no exclusiva de distribución de la versión de la obra publicada (p. ej.: depositarla en un archivo telemático institucional o publicarla en un volumen monográfico) siempre que se indique la publicación inicial en esta revista.
- Se permite y recomienda a los autores/as difundir su obra a través de Internet (p. ej.: en archivos telemáticos institucionales o en su página web) antes y durante el proceso de envío, lo cual puede producir intercambios interesantes y aumentar las citas de la obra publicada. (Véase El efecto del acceso abierto).











2022